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Abstract: Breast cancer is the most common cancer and leading cause of cancer death among women
worldwide, encompassing a wide heterogeneity of subtypes with different clinical features. During
the last two decades, the use of targeted therapies has emerged in clinical research in order to increase
treatment efficiency, improve prognosis and reduce recurrence. However, the triple negative breast
cancer (TNBC) subtype remains a clinical challenge, with poor prognosis since no therapeutic targets
have been identified. This aggressive breast cancer entity lacks expression of oestrogen receptor (ER)
and progesterone receptor (PR), and it does not overexpress human epidermal growth factor receptor
2 (HER2). The major reason for TNBC poor prognosis is early therapeutic escape from conventional
treatments, leading to aggressive metastatic relapse. Metastases occur after an epithelial-mesenchymal
transition EMT of epithelial cells, allowing them to break free from the primary tumour site and to
colonize distant organs. Cancer-associated EMT consists not only of acquired migration and invasion
ability, but involves complex and comprehensive reprogramming, including changes in metabolism,
expression levels and epigenetic. Recently, many studies have considered epigenetic alterations as the
primary initiator of cancer development and metastasis. This review builds a picture of the epigenetic
modifications implicated in the EMT of breast cancer. It focuses on TNBC and allows comparisons
with other subtypes. It emphasizes the role of the main epigenetic modifications lncRNAs, miRNAs,
histone and DNA- modifications in tumour invasion and appearance of metastases. These epigenetic
alterations can be considered biomarkers representing potential diagnostic and prognostic factors in
order to define a global metastatic signature for TNBC.
Keywords: triple negative breast cancer TNBC; epithelial-mesenchymal transition EMT; epigenetic
modifications; long non-coding RNAs LncRNAs; miRNAs; histone modifications; DNA
methylation; metastasis
1. Introduction
Although mortality associated with breast cancer has been constantly declining over the last
20 years, there were still more than 626,000 deaths worldwide in 2018 (International Agency for Research
on Cancer IARC 2018 Breast Cancer Statistics). A major reason for these therapeutic failures is the
wide heterogeneity of breast cancer and distant metastases. Fifteen years ago, molecular classification
of these cancers paved the way for targeted therapeutic approaches taking into account the specificities
of different subtypes of breast cancer [1,2].
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Triple Negative Breast Cancer (TNBC) is a highly aggressive subtype, accounting for 10–20%
of all diagnosed breast cancers, with no targeted therapy available due to the lack of oestrogen
and progesterone receptor expression and the absence of HER2 amplification [3]. Representing a
serious clinical therapeutic challenge, TNBC is characterized by poor overall survival, early relapse
and most importantly, frequent distant metastasis [3]. A lethal hallmark of cancer, metastasis of
TNBC is correlated with aberrant activation of epithelial-mesenchymal transition (EMT) [4,5]. EMT
is a fundamental biological mechanism by which epithelial cells acquire a mesenchymal phenotype
by gaining migratory and invasive properties and modifying cell adhesion molecules [4,5]. This
differentiation process is important during development, but inhibiting EMT by antagonizing the
EMT-related mesenchymal cell markers such as αvβ3 integrin reveals its massive involvement in
TNBC aggressiveness and metastasis [6]. It allows triple negative epithelial breast cancer cells to
break free from their primary tumour site and eventually to colonize distant organs developing
metastasis [4,5]. During the last decade, a large amount of data and knowledge were acquired on
TNBC biomarkers. Chemokine C-C motif ligand 5 (CCL5), interleukin 17B, transforming growth factor
β (TGF-β), placental growth factor, CXCL10 and platelet-derived growth factor receptor β (PDGFRβ)
were considered as biomarkers for TNBC aggressiveness and progression. These biomolecules were
involved in the recruitment of bone marrow-derived mesenchymal stem cells (BM-MSCs), which play
a crucial role in multiple EMT program mechanisms (cell migration and invasion, neo-angiogenesis,
promoting extracellular matrix remodelling . . . ), towards TNBC sites [7]. Cancer-associated EMT
requires complex and comprehensive reprogramming, including changes in metabolism, expression
levels and epigenetic [4,5].
From a molecular point of view, EMT is characterized by the loss of E-cadherin, claudin and
cytokeratin expression, and the overexpression of N-cadherin and vimentin, which are respectively
epithelial and mesenchymal cell markers [5]. Partial EMT leads to cells with a mixed phenotype,
called “metastable”. Several major pathways are involved in the EMT, including TGF-β, NF-κB, WNT,
NOTCH, HIF1/2 and RAS-ERK1/2. Most of these interact with transcription factors implicated in the
modulation of E-cadherin expression such as Snail, Slug, ZEB1, ZEB2, E47, Twist, and KLF8 [5].
As researchers continue to illustrate the effect of epithelial-mesenchymal plasticity on tumour
progression and to investigate its invasion-related molecular mechanism, a clearer perception of the
general epigenetic modifications in malignant cells undergoing EMT is now appearing. Nevertheless,
the current state of art of the precise role of epigenetic regulators in controlling both EMT and MET
processes in tumorigenesis including TNBC are not fully understood yet. In sharp contradiction with
EMT inducing factors and transcription factors, we are just now beginning to understand how those
alterations induce EMT and MET or function to maintain epithelial and mesenchymal phenotypes. For
this reason, the exact epigenetic regulation remains a frontier to discover.
We hypothesize that close interactions between different EMT inducing factors and TFs and
epigenetic regulators exist. EMT-related factors and markers are targets of epigenetic regulations.
Epigenetic modifiers must also be regulated by TFs to transcriptionally regulate epithelial and
mesenchymal genes during EMT. For example, TFs may be responsible for the expression of epigenetic
factors activating or repressing in return the expression of EMT-markers. The understanding of these
probable functional interactions controlling the inter-conversion between epithelial and mesenchymal
phenotypes may provide new opportunities and novel therapeutic approaches aiming towards the
prevention of cancer invasion and metastasis, based on the development of individualized epigenetic
cancer therapy.
A lot of work has been published on TNBC, and mutations and modifications of expression
levels are now well described. In our review, we would discuss the current state-of-the-art and latest
findings regarding the implication of epigenetic modifications in EMT. We would emphasize on the
role of four major epigenetic modifications in the regulations of the EMT of TNBC responsible for
distant metastases, describing the various molecular pathways implicated as well as a large number of
transcription factors influenced by the deregulation of these factors. They include non-coding RNA,
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both long-non-coding RNAs (lncRNAs) and micro RNA (miRNAs), and modifications at the level of
histones or DNA, such as acetylation or methylation.
For each class of epigenetic factors (lncRNA, miRNA, histone or DNA modification), we first
present large screening studies that provide lists of candidates specifically dysregulated in TNBC.
These general studies pave the way for targeting TNBC through the identification of high impact
candidate genes and factors. However, from one study to another, the sets of genes often overlap
poorly, and functional validation is required. Thus, in the second part of each chapter, we focus on
studies describing the role of epigenetic factors involved in the EMT of TNBC. The functional evidences
are not paraphrased for each factor, but they are gathered in Tables 1–5 and a comprehensive network
assembles all interactions in Figure S1 (Supplementary Material). Further genes are pending for
validation in order to identify novel prognostic factors and therapeutic targets. A number of essential
anti-TNBC drugs used (Table 4) and a description of primary applied clinical trials are discussed in
this paper.
2. Long Non-Coding RNAs
Long non-coding RNAs (lncRNAs) are transcribed RNA molecules not encoding any protein,
with a length over 200 nucleotides [8]. Due to the lack of experimental tools and overall knowledge,
the function of lncRNAs was largely unknown until the early 1990′s when H19 and Xist were found to
be involved in epigenetic modulations [9]. Since the publication of the human genome in 2001 and
the finding that only 2% of the genome encodes for proteins despite the fact that >90% is actively
transcribed [10], extensive attention has been given to long non-coding RNAs in order to investigate
their biological and regulatory activity. While considering that dysregulation of lncRNAs is well
described in many human disorders, such as cardiovascular disease [10], prior investigations have
shown that dysregulation of lncRNAs plays a critical role in cancer progression, as oncogenic or
tumour-suppressor genes by modulating tumour cell death, proliferation, migration, invasion and
drug resistance [11]. In recent years, researchers were highly interested in the role of lncRNAs in
several subtypes of breast cancer including TNBC [12–16]. LncRNAs have been reported as promising
diagnostic biomarkers, prognostic factors and potentially efficient therapeutic targets by a set of
systematic research described further down. Moreover, these studies have evaluated the role of single
lncRNAs for different endpoints, such as overall survival OS, progression-free survival PFS, poor
prognosis, and TNBC proliferation and metastasis.
Lately, abnormal expression of lncRNAs, related altered mechanisms and primary deregulation
were the subject of pivotal studies presented later.
In a microarray analysis study, a set of 1403 unique lncRNAs, with 853 up-regulated and 550
down-regulated, was discovered to be differentially expressed between TNBC and non-tumourous
tissues, suggesting a pivotal role of lncRNAs in TNBC progression [17]. In the aim of offering specific
therapeutic targets and promising diagnosis biomarkers, a core group of onco-lncRNAs was identified.
Another set of 1211 differentially expressed TNBC-specific lncRNAs among the wide dysregulated
lncRNAs was defined by co-expression networks [18].
Furthermore, a lncRNA expression signature of four lncRNAs (IGKV, RP11-434D9.1, BC016831,
and LINC00052) differentially expressed between TNBC and non-TNBC tissues was validated [19].
Recently, a re-mapping strategy generated novel data allowing the discovery of additional differentially
expressed lncRNAs in TNBC. Sixty one recent lncRNAs were identified, where thirty-three lncRNAs
were downregulated (Top five: lnc-PAPLN-2:1, lnc-FLT3LG-1:7, lnc-NEK8-2:1, lnc-FLOT2-1:1 and
lnc-ZNF75D-2:2) and twenty eight lncRNAs were upregulated (Top five: lnc-DNAJC16-1:1, lnc-SC5DL-3:1,
lnc-PURA-2:1, lnc-EIF2C2-1:1 and lnc-ELP4-3:1) [20].
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From our intention to review the recent advances in this field evaluating the crucial role of each
lncRNA in a single study separately in the outcome of the ‘invasion-metastasis cascade’ in TNBC
patients, a set of EMT specific lncRNAs are presented. lncRNAs involved in EMT of TNBC could be
assigned to two classes based on the level of expression and molecular regulation. First, lncRNAs
LET [21], Xist [22], lncRNA-CTD-2108O9.1 [23], and GAS5 [24] were shown to be downregulated in
TNBC cell lines. Upregulation of these lncRNAs attenuates TNBC cell proliferation and viability
and enhances apoptosis. In addition, the overexpression of these lncRNAs inhibits TNBC growth,
invasion and migration, and represses EMT by increasing E-cadherin expression as well as decreasing
N-cadherin and Vimentin expression. The mechanisms by which this category of lncRNA acts differ
from one lncRNA to another. XIST exerts its suppressive activity via miR-155/CDX1 [22], GAS5 by
functioning as a competing endogenous RNA (ceRNA) that antagonizes miR-196a-5p targeting thereby
FOXO1/PI3K/AKT signalling [24], lncRNA-CTD-2108O9.1 targets leukemia inhibitory factor receptor
LIFR [23], while no specific molecular mechanism for LET is yet defined [21]. (see Figure S1 and
Table 1).
Twenty-three different lncRNAs investigated in separated studies were reported to be pro-tumoural
agents, usually correlated with a high capacity of TNBC progression and metastasis, poor overall
survival and early outcome. Knockdown of these upregulated TNBC lncRNAs leads eventually to
the suppression of cell motility along with TNBC metastasis and invasion and to the inhibition of
EMT molecular marker expression. The mechanisms of actions of these lncRNAs, MALAT1 [25–27],
HOTAIR [28], SNHG12 [29], LINC01638 [30], H19 [31], Linc-ZNF469-3 [32], LINC00673 [33], lnc-ATB [34],
HOXA11-AS [35], OR3A4 [36], MIAT [37], GHET1 [38], AC026904.1/UCA [39], NNT-AS1 [40], PVT1 [41],
ARNILA [42], lncRNA-RoR [43], LINC00518 [44], ADAM/lnc015192 [45], LOC554202 [46], and snaR [47]
are summarized in Table 1 (see Figure S1).
Among these two profiles, some lncRNAs, GAS5 [24], MIAT [37], ARNILA [42], NNT-AS1 [40],
lnc015192 [45], and UCA [39] are able to directly regulate EMT pathways and TNBC invasion by
functioning as ceRNAs for EMT-regulating-RNA via sharing common sequences with them (see
Figure S1 and Table 1).
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Table 1. Significant lncRNAs implicated in EMT of TNBC.
lncRNAs Targets Genes and Pathways Implicated Sense of Dyregulation in TNBC Role of LncRNA in TNBC References
LET Downregulated Anti-tumoural [21]
XIST miR-155 CDX1 Downregulated Anti-tumoural [22]
lncRNA-CTD-2108O9.1 LIFReceptor JAK/STAT and MAPK pathway Downregulated Anti-tumoural [23]
GAS5 miR-196a-5p FOXO1/PI3K/AKT pathway Downregulated Anti-tumoural [24]
MALAT1
MALAT1/HuR (ELALV1) complex
miR-1
miR-129-5p
–
Slug
–
CD133
Up-regulated
Up-regulated
Absence of complex
Pro-tumoural
Pro-tumoural
Anti-tumoural
[25]
[26]
[27]
HOTAIR Up-regulated Pro-tumoural [28]
SNHG12 MMP13 Up-regulated Pro-tumoural [29]
LINC01638 c-MycMTDH-Twist1 pathway up-regulated Pro-tumoural [30]
H19 miR-675 ubiquitin ligase E3 family (c-Cbl and Cbl-b) Up-regulated Pro-tumoural [31]
Linc-ZNF469-3 miR-574-5p ZEB1 Up-regulated Pro-tumoural [32]
LINC00673 NCR3LG1(B7-H6) Up-regulated Pro-tumoural [33]
Lnc-ATB miR-141-3p ZEB1 and ZEB2 Up-regulated Pro-tumoural [34]
HOXA11-AS Up-regulated Pro-tumoural [35]
OR3A4 Up-regulated Pro-tumoural [36]
MIAT
(ceRNA) miR-155-5p DUSP7 Up-regulated Pro-tumoural [37]
GHET1 Up-regulated Pro-tumoural [38]
AC026904.1 and UCA (ceRNA) Slug Up-regulated Pro-tumoural [39]
NNT-AS1
(ceRNA) miR-142-3p ZEB1 Up-regulated Pro-tumoural [40]
PVT1 P21 Up-regulated Pro-tumoural [41]
ARNILA (ceRNA) miR-204 Sox4 Up-regulated Pro-tumoural [42]
LncRNA-RoR miR-145 ARF6 Up-regulated Pro-tumoural [43]
LINC00518 CDX2 and Wnt signaling pathway Up-regulated Pro-tumoural [44]
ADAM and lnc015192 (ceRNA) miR-34a Up-regulated Pro-tumoural [45]
LOC554202 Up-regulated Pro-tumoural [46]
snaR Up-regulated Pro-tumoural [47]
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3. MiRNAs
MicroRNAs (miRNAs) are small noncoding RNAs approximately 22 nucleotides long, involved
in the regulation of posttranscriptional gene expression [48]. Aberrant miRNA expression has been
associated with cancer cell progression, invasion and metastasis, acting both as oncogenes and tumour
suppressors [49–55]. miRNAs are also powerful drivers of metastasis in many malignancies by
regulating non-EMT-related and/or EMT–related mechanisms [56].
As miRNAs are smaller and more stable than mRNAs in formalin-fixed paraffin-embedded (FFPE)
tissues and accessible body fluids, their expression was the subject of multiple investigations mentioned
later, as potential TNBC biomarkers in order to give insight into their role in TNBC progression and
invasion along with the appearance of distant metastasis. A number of general studies evaluating a
panel of miRNAs by different technics are described lately.
Recently, using the robust rank aggregation (RRA) method, metasignatures of six significantly
dysregulated miRNAs: two downregulated: hsa-miR-449a and hsa-miR-190b and four upregulated:
hsa-miR-9-5p, hsa-miR-18a-5p, hsa-miR-135b-5p and hsa-miR-522-3p, were identified from different
studies, with high prediction accuracy. The gene ontology analysis revealed the top 10 preferred
target genes and 10 pathways of metasignature miRNAs in TNBC suggesting promising candidate for
diagnostic biomarkers in TNBC [57].
Four miRNA signatures in TNBC given by miR-155, miR-493, miR-30e and miR-27a expression
levels were identified allowing a new stratification of TNBC based on the level of patient outcome.
Defined as “risk”-associated, down-regulation of miR-27a and miR-30e is correlated with worse patient
outcome, while upregulation of miR-493 and miR-155 associated with better outcome is described as
“protective” [58].
Furthermore, miRNAs expression profile generated by limma algorithm identified 67 significantly
differentially expressed miRNAs (DEmiRNAs) between TNBC and normal tissues. Among them
21 were down-regulated (Top five: hsa-mir-486-1, hsa-mir-486-2, hsa-mir-4732, hsa-mir-139 and
hsa-mir-451a) and 46 up-regulated (Top five: hsa-mir-105-1, hsa-mir-519a-1, hsa-mir-105-2, hsa-mir-767
and hsa-mir-516a-1) [59].
Further profiling of miRNAs expression in TNBC cells identified four candidate miRNAs (miR-26a,
miR-153, miR-10b and miR-146a) as potential TNBC biomarkers. Exogenous expression assays reported
that miR-26a and miR-10b suppress BRCA1 expression in MDA-MB-231 and MCF-7 cells, while BRCA1
expression was downregulated by miR-153 only in MCF7 cells. High expression of miR-146a in TNBC
cells compared to non-TNBC was validated by in silico analysis of The Cancer Genome Atlas (TCGA)
data [60].
Seven other miRNAs (miR-300, miR-382, miR-494, miR-495, miR-539, miR-543, and miR-544) in the
imprinted DLK1-DIO3 region are known to cooperatively repress EMT. DLK1-DIO3 miRNAs target
EMT-inducing molecules repressing a signaling network comprising ZEB1/2, TWIST1, BMI1, and
miR-200 family miRNAs. Thus, silencing the cluster by hypermethylation of upstream CpG islands
in MDA-MB-231 cells represents a key early step that promotes loss of CDH1 expression, initiates
EMT, and activates tumour cell invasion and metastasis [61]. Three main members (miR-200 a, b
and c) of the miR200 family are considered as tumour suppressor miRNAs restraining EMT. These
miRNAs targeting E-cadherin suppressors ZEB1, ZEB2 and SUZ12 are downregulated in TNBC cells,
representing a promising therapeutic target [62–64] (see Figure S1 and Table 2).
Given that many lncRNAs act as competing endogenous lncRNA (ceRNA) to sequester miRNAs,
and since miRNAs rank among the main drivers of EMT in many malignancies, this report aims
to generate a general summary of all miRNAs differentially expressed in TNBC, as promising new
therapeutic targets and novel molecular biomarkers for TNBC. Several data suggest that chromatin
modifications are correlated with differential expression of lncRNAs and miRNAs in TNBC. Promoter
hypermethylation was shown to be one of the major mechanisms to silence miR-200c/miR-141 and
LOC554202/miR-31 locus [46,64]. It is very likely that the same regulation occurs with other lncRNAs
and miRNAs involved in the EMT of TNBC.
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Table 2. Major miRNAs involved in EMT of TNBC.
miRNAs Targets and Pathways Sense of Dyregulation in TNBC Role of miRNA in TNBC References
miR-31 Downregulated Anti-tumoural [46]
DLK1-DIO3 region (miRs 300, 382, 494, 495, 539, 543, and 544) TWIST1, BMI1, ZEB1/2, and miR-200 family Downregulated Anti-tumoural [61]
miR200a
ZEB1, ZEB2 and SUZ12
E-cadherin pathway
EPH receptor A2 (EPHA2)
EPHA2 pathway
Downregulated Anti-tumoural [62]
miR200b PKCα/Rac1 Downregulated Anti-tumoural [63]
miR-200c ZEB1 Downregulated Anti-tumoural [64]
miR-30a Inhibition of ROR1 Downregulated Anti-tumoural [65]
miR-146a Inhibition of RhoA Downregulated Anti-tumoural [66]
miR-143-3p LIMK1 expressionLIMK1/CFL1 pathway Downregulated Anti-tumoural [67]
miR-200b-3p/miR-429-5p LIMK1 expressionLIMK1/CFL1 pathway Downregulated Anti-tumoural [68]
miR-139-5p TGF-β, Wnt, MAPK, and PI3K Downregulated Anti-tumoural [69]
miR-212-5p Prrx2Wnt/β-catenin pathway Downregulated Anti-tumoural [70]
miR-199a-5p Downregulated Anti-tumoural [71]
miR-155 Downregulated Anti-tumoural [72]
miR-34c-3p MAP3K2MAP3K2 pathway Downregulated Anti-tumoural [73]
miR-3178 Notch1 Downregulated Anti-tumoural [74]
miR-200b-3p Downregulated Anti-tumoural [75]
miR-125b MAP2K7MAPK pathway Downregulated Anti-tumoural [76]
miR-655 Prrx1 Downregulated Anti-tumoural [77]
miR27-a PTEN, PKBPI3K/AKT pathway Up-regulated Pro-tumoural [78]
miR-182
Inhibition of FOXF2
PFN1
Up-regulated
Up-regulated
Pro-tumoural
Pro-tumoural
[79]
[80]
miR-454 PTENPI3K/AKT pathway Up-regulated Pro-tumoural [81]
miR-373 HIF1α and TWISTHIF1α-TWIST pathway Up-regulated Pro-tumoural [82]
miR-221/222 ADIPOR1 and TRPS1NF-κB, IL6, and JAK2/STAT3 pathway Up-regulated Pro-tumoural [83]
miR-10b TGF-β1-induced EMT pathway Up-regulated Pro-tumoural [84]
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Among the numerous miRNAs identified by these large screening assays, single studies aiming
to investigate the precise performance of some specific miRNAs in the EMT of TNBC were proceeded.
The goal was to determine the level of miRNAs expression in TNBC highly metastatic cells in vitro and
to alter this expression. The analysis of epithelial and mesenchymal markers was used to determine
the anti- or pro-metastatic role of the candidate miRNAs. For a number of these miRNAs, target genes
were predicted and tested in order to identify the specific mechanism of action of the miRNAs.
A set of twenty two miRNAs correlated with EMT and TNBC cell migration and invasion
suggesting a leading role in influencing the expression levels of their target genes and pathways can be
established: miR-30a [65], miR-146a [66], miR-143-3p [67], miR-200b-3p/miR-429-5p [68], miR-139-5p [69],
miR-212-5p [70], miR-199a-5p [71], miR-155 [72], miR-34c-3p [73], miR-3178 [74], miRNA-200b-3p [75],
miR-125b [76], and miR-655 [77], were outlined as down regulated while miR27-a [78], miR-182 [79,80],
miR-454 [81], miR-373 [82], miR-221/222 [83], and miR-10b [84] were reported as up regulated (see
Figure S1 and Table 2).
4. Histone Modifications
N-terminal modifications of histones, including acetylation and methylation, as well as the
reverse of these processes frequently observed in cancer, are responsible for modifying the secondary
DNA structure and the accessibility of transcription factors to gene promoter regions regulating gene
transcription [85–87]. In breast cancer, histones modifications play a major role in cell proliferation,
induced apoptosis and metastatic ability [88].
Discussing histone modifications mechanisms in TNBC especially, surveys proposed an interesting
performance for histones modifications in the appearance and progression of TNBC [89–91]. Despite
the not fully understood effect of histones alterations, histone modification inhibitors, such as
histone deacetylase inhibitors (HDACis) have emerged as a promising new class of multifunctional
anticancer agents preventing TNBC growth and metastasis [92]. These inhibitors could also help to
better understand the effect of histone modifications on the outcome and the metastasis of TNBC
through gene expression regulation in order to define new biomarkers and targeted therapies [92,93].
Nonetheless, two HDACis used together with ionizing radiation, autophagy and kinase inhibitors
were the subject of multiple investigations [94–96].
Identifying major histone alteration’s delineation in TNBC as well as principle genes influenced
by these modifications is the subject of upcoming surveys. A specific histone modification profile
identified eight key histone modifications (H3K9me3, H3K9ac, H3K27ac, H3K4me3, H3K27me3, H3K4me1,
H3K36me3 and H3K79me2) in four different TNBC cell lines (MDA-MB-231, MDA-MB-468, MDA-MB-436,
and HCC1937) among thirteen cell lines [97]. Intriguingly, a TNBC specific gene was also identified:
Actin Filament Associated Protein Antisense RNA 1 (AFAP1-AS1), an anti-sense lncRNA marked by
numerous active histone modifications, such as H3K79me2 and H3K4me3, suggesting a role in tumour
EMT and progression. The same study showed that a new histone acetyltransferase NAA60, which
mediates acetylation events in H4 such as H4K20ac, H4K79ac and H4K91ac, was silenced in TNBC [97].
Furthermore, a global map of histone H3 methylation (H3K4me3) and acetylation (H3K4ac) profiles
in MDA-MB-231 cells showed an association of H3K4me3 with late-stage cancer cells, while gain of
H3K4ac was correlated with cancer-related phenotypic traits, especially EMT pathways [98].
Histone methyltransferases (HMTs) catalyse the methylation of lysine and arginine residues.
Genetic modifications of HMTs affect tumour progression and metastasis. Four HMTs (ASH1L, SETDB1,
and SMYD3) presented higher amplification frequencies in basal-like breast cancer (a subtype of
TNBC) while eight HMT expression levels (EZH1, SMYD3, EHMT1, SETD7, PRDM4, SETD3, SETD1B,
and PRDM6) were significantly downregulated and twelve HMT expression levels (EZH2, PRDM15,
PRDM13, SMYD2, SMYD5, SUV39H1, SUV39H2, EHMT2, WHSC1, SETD8, SETDB and SETD6) were
significantly up-regulated comparing basal-like to other breast cancer subtypes [99].
A multi-parametric RNAi screening approach identified 70 gene candidates involved in EMT.
Among them, three histone alteration modulators, histone methyltransferase G9a, H3K79 methylator
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DOT1L and a new histone acetyltransferase KAT5, were shown to be up-regulated, repressing CDH1
and enhancing EMT [100].
DNMTi SGI and HDACi MS275 have been proposed as combined treatment for TNBC able
to epigenetically reverse EMT and inhibit cell motility, proliferation and colony formation. This
anti-EMT/antitumour activity is exerted by impeding EpCAM cleavage and the WNT pathway,
repressing abnormal p53, EZH2, and ZEB1, and by promoting E-cadherin and apoptosis, together with
histone H3 tri-methylation [101].
DNA damage-specific histone chaperone aprataxin PNK-like factor (APLF), significantly enhanced
in TNBC, was reported as an essential TNBC biomarker and a treatment target. Downregulation
of APLF upregulates E-cadherin (CDH1) expression and suppresses EMT related genes inhibiting
MDA-MB-231 cell invasion and metastasis [102].
Based on histone modifications profiling, several studies aimed to reconstitute the normal
expression level of epigenetically deregulated genes. For this reason, metastatic TNBC cells have been
treated with specific histone modifiers inhibitors to investigate their ability to induce or reduce TNBC
metastasis and to evaluate their global effect on the TNBC EMT. Furthermore, the effect of depletion
of upregulated histones modifiers on migration and invasive characteristics has been investigated in
TNBC metastatic cells. Variations of epithelial and cell adhesion markers were also analysed in order
to understand the roles of histone modifications on EMT and, eventually, identify potential diagnostic
and prognostic biomarkers.
The role of multiple histone alteration effectors in inducing or reversing EMT in TNBC are listed in
Table 3 (see Figure S1). EMT-repressive factors TIP 60 [103] and KDM6A [104] and EMT-inductive factors
EZH2 [105], LSD1 [106], hSETD1A [107], JMJD5 [108], KDM5B [109], KDM3A [110] and HDAC8 [111]
have been investigated in multiple studies (Table 3 and see Figure S1). Histone modification inhibitors
used in studies evaluating the role of specific histone modification treatments in promoting or inhibiting
the EMT of TNBC are listed in a supplementary table (Table 4 and see Figure S1). The mechanisms of
treatment of the histone deacetylase inhibitors vorinostat (SAHA) [94,112], panobinostat (LBH589) [93],
entinostat (ENT) [113,114], trichostatin A (TSA) [115] and HTPB [116], as well as the lysine demethylase
inhibitor parnate (PCPA) [117], and the histone methyltransferase inhibitor UNC0638 [118], along with
their main role in reversing EMT are listed in Table 4 (see Figure S1).
5. DNA Methylation
DNA methylation is the first and the best-described epigenetic modification in tumours
characterized by abnormal activity of DNA methyltransferase enzymes (DNMTs), principally
DNMT1 [118]. Two main characteristics delineate the cancer epigenome; gene-specific
hyper-methylation and global DNA hypo-methylation [119]. Gene-specific hyper methylation of
caretaker and tumour suppressor genes is caused by cytosine methylation in CpG islands, which is
a recognized epigenetic silencing marker and a key factor in breast carcinogenesis [119–121]. The
identification of differentially methylated regions (DMRs) enriched with promoters associated with
DNA hypersensitive sites and transcription factor binding sites can be used to sort TNBCs into three
different methylation clusters with different prognosis. Three DMRs were associated with good
survival, while fourteen DMRs were associated with poor survival [122].
A diverse set of DNA methylation signatures predicting TNBC treatment response, identifying
different breast cancer subtypes with significant diagnostic and prognostic potential have been
presented by many studies.
First, an association is strongly suggested between the loss of expression of epithelial biomarkers
and gene promoter hypermethylation events in human TNBC. Comparison of the hypermethylation
of 110 CpGI in 69 cancer-related genes between TNBC and non-TNBC revealed a similar number of
methylated CpGI but a different list of methylated genes [123].
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Table 3. Histone modification factors associated with EMT of TNBC.
Histones Modifications
Factors Targets and Pathways
Sense of
Dyregulation in
TNBC
Role of histone
modifications in
TNBC
References
TIP60
Lysine acetyltransferase
Destabilize DNMT1 and inhibit SNAIL2 function leading to the inhibition of DNA
methylation of EpCAM promoter region activating the expression of epithelial
markers.
Downregulated Anti-tumoural [103]
KDM6A
H3K27me3-demethylase
Maintenance of CDH1/E-cadherin levels.
Role in the MET-associated resolution.
Reactivation of bivalent genes by removing H3K27me3
marks deposited during EMT.
Downregulated Anti-tumoural [104]
EZH2
Histone-lysine
N-methyltransferase (H3K27me3)
Induce the repression of TIMP2 transcription increasing MMP-2 and MMP-9 activity. Up-regulated Pro-tumoural [105]
LSD1
Lysine demethylase 1
Represses E-cadherin expression by demethylating H3K4me at gene’s promoter,
during which phosphorylation of LSD1 Ser112 is crucial. Up-regulated Pro-tumoural [106]
hSETD1A
H3K4 Methyltransferase Activates MMPs expression (MMP2, MMP9, MMP12, MMP13, and MMP17). Up-regulated Pro-tumoural [107]
JMJD5
H3K36me2 demethylase
Promote cell invasion and induce EMT.
Catalyze Snail promoter H3K36me2 demethylation activating its expression. Up-regulated Pro-tumoural [108]
KDM5B
Lysine-specific demethylase 5B
Overexpress MALAT1.
Overexpress EMT markers, c-Met, Slug and N-Cadherin, and inhibitis E-Cadherin. Up-regulated Pro-tumoural [109]
KDM3A
H3 lysine 9 demethylase 3A
Promotes the expression of invasive genes by erasing H3K9me2 marks.
Regulates the expression of MMP-9 and JUN expressions. not evaluated Pro-tumoural [110]
HDAC8
Zinc-dependent class I HDAC
Enhance TNBC cell migration.
Regulates YAP protein levels by decreasing YAP phosphorylation at Ser127. not evaluated Pro-tumoural [111]
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Table 4. Role of histone modification inhibitors.
Treatment Mechanisms References
Panobinostat (LBH589)
Histone deacetylase inhibitor
Increases CDH1 protein expression and morphology changes in MDA-MB-231 cells.
Reverse EMT [93]
Suberoylanilide hydroxamic acid (SAHA) or
Vorinostat
pan-HDAC inhibitor
Suppress metastasis by Inhibiting MMP-9 activity
Promote EMT of TNBC cells via HDAC8/FOXA1 signals
Downregulate E-cadherin
Upregulate N-cadherin, vimentin and fibronectin
[94]
[112]
Entinostat (ENT)
Class I HDAC (nuclear) inhibitor
Increases E-cadherin transcription
Reduces in N-cadherin mRNA expression
Downregulates snail and twist
Increases vimentin phosphorylation
Increases vimentin filaments’s remodeling
Reduces formation of tubulin-based microtentacles
Upregulates cytokerain 8/18
Reverse EMT
Reduce the percentage of TIC cells from TNBC cells.
Reduce the CD44high/ CD24 low cell population, ALDH-1 activity, and protein and mRNA
expression of known TIC markers such as Bmi-1, Nanog, and Oct-4.
[113]
[114]
Trichostatin A (TSA)
HDAC inhibitor
Reverse EMT
Upregulate E-cadherin and suppresses Slug and Vimentin [115]
HTPB
pan-HDAC inhibitor
Inhibits integrin-b1/FAK/MMP/RhoA/F-actin pathways.
Suppress tumour metastasis [116]
Parnate (PCPA)
Lysine demethylase 1 LSD1 inhibitor
Blockage of Slug/LSD1 interaction
Induces the expression of E-cadherin and other epithelial markers [117]
UNC0638
Histone methyltransferase inhibitor
Restores E-cadherin and vimentin via modulating the Snail-G9a axis in order to block CSCs
properties and reverse EMT. [118]
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A specific methylation profile of sixteen cancer-related genes specific to TNBC was defined by
the non-methylation of eleven genes (MSH2, MLH1, MSH3, MSH6, CACNA1A, CACNA1G, GSTP1,
ID4, PMS2, DLC1, and TWIST1) and the methylation of five genes (RB, CD44, CDKN2B, MGMT, and
p73) [123].
Among 38 genes identified as deregulated in TNBC, whole genome DNA methylation analysis
revealed an essential role of DNA methylation in modifying the expression of 16 TNBC-specific genes
expression. Only IL6ST showed significantly altered methylation in three probes allowing it to be
classed as a DMR [124].
The analysis of EMT-related marker expression in TNBC described a new signature for TNBC
subclasses, based on the association of CD146 or MCAM expression (an EMT inducer) with the
expression of EMT and breast cancer stem cell (BCSC) (CD44+/CD24−) markers, and suggested that
ZEB1 expression as a promising biomarker for poor clinical outcome [125].
Aside from DNA methylation inhibition of anti-tumour genes, hypermethylation or
hypomethylation of miRNA were responsible for main miRNAs deregulation mentioned above.
Addition to the pro-tumour miRNAs up-regulated in TNBC by the absence of methylation, a set of
miRNAs displaying anti-tumour characteristics were epigenetically inactivated by DNA methylation
(DLK1-DIO3 cluster, miR126, miR195, miR497, miR148a, miR152 and miR-200 family) [126].
A TNBC gene expression signature has been linked to aberrant promoter CpG hypermethylation of
nine epigenetic biomarker genes (CDH1, CEACAM6, CST6, ESR1, GNA11, MUC1, MYB, SCNN1A, and
TFF3). The loss or reduced level of methylation-sensitive gene products was defined as a fundamental
characteristic of TNBC, and associated with poor long-term survival [127].
Several genes chosen from the DNA-methylation-based profiles were evaluated in separated
studies. The impact of epigenetic inactivation was evaluated after methylation of their promoter and
correlated to the outcome of metastasis in TNBC invasive cells. Demethylation treatments restoring
the expression of target genes changed the progressive character of TNBC cell, allowing the definition
of the promoter methylation impact on EMT. The identification of the signalling pathways impacted
by this methylation enlightened on target gene functions and may lead to establish novel TNBC gene
therapeutic strategies.
Finally, many studies have evaluated the role of DNA methylation in TNBC by inhibiting the
regulatory sequences methylation of a number of specific genes. CREB3L1 [128], BRMS1 [129],
DACT2 [130], WWC1 [131] and ADAMTS18 [132] with anti-EMT activity were shown to be
down-regulated in TNBC, while FOXF2 [133] and DKK2 [134] exerting pro-EMT activity were
upregulated in TNBC; suggesting that DNA methylation is a leading source of the expression
deregulation and TNBC high metastasis capacity (see Figure S1 and Table 5).
6. Clinical Trials
Interpretation of clinical trials related to TNBC remains very complex due to the heterogeneous
response to systemic therapy. In the last decade, multiple clinical trials have been conducted
to control TNBC growth and metastasis, in order to define new targeted therapies and novel
biomarkers. Furthermore, targeting PI3K, AKT, HDAC, PD-1, AR and Hsp 90 in metastatic TNBC
with specific inhibitors and antagonists was the topic of a substantial number of clinical trials,
including NCT01629615, NCT01790932, NCT02162719, NCT02353988, NCT02457910, NCT02657889,
NCT02513472, NCT02768701, NCT02734290, NCT01349959, NCT02898207 and NCT02474173.
Moreover, the effect of different drugs such as dasatinib, iniparib, epalrestat, tinostamustine and
others was evaluated in various clinical studies NCT00371254, NCT01173497, NCT03244358, and
NCT03345485, in the search of therapeutic biomarkers for metastatic TNBC.
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Table 5. DNA modifications implicated in the induction of EMT.
Genes Targets and Pathways Sense of dyregulationin TNBC
Role of DNA
methylation in TNBC References
CREB3L1
Methylation of several key CpG sites
Metastasis suppressor
Activates p21 expression
Suppresses cancer cell survival and angiogenesis genes.
Downregulated Anti-tumoural [128]
BRMS1
Promoter hypermethylation
Metastasis suppressor.
Downregulates several metastasis-related genes through modulating
the activity of NF-kB, including osteopontin (OPN), urokinase-type
plasminogen activator (uPA), micro-RNA-146, interleukin-6 (IL-6)
and chemokine receptor 4 (CXCR4).
Downregulated Anti-tumoural [129]
DAPPER2 (DACT2)
Promoter CpG methylation
Metastasis suppressor by antagonizing Wnt/β-catenin and
Akt/GSK-3 signaling. Downregulated Anti-tumoural [130]
WWC1
H3K27me3 inhibition catalysed by EZH2
and CpG island methylation mediated by
DNMT1 within the wwc1 promoter
Code for Kibra protein.
EMT suppressor by regulating the Hippo/ YAP tumour suppressor
pathway.
Downregulated Anti-tumoural [131]
ADAMTS18
Promoter methylation
Deregulates AKT and NF-κB signaling, by inhibiting
phosphorylation levels of AKT and p65. Downregulated Anti-tumoural [132]
FOXF2
Absence of promoter methylation
Functions as a promoter for EMT and metastasis.
Regulates genes involved in controlling cell cycle
progression and EMT, and is co-expressed with EMT genes
SNAI2/Slug and Vimentin and a metastasis-promoting gene GLI2.
Up regulated Pro-tumoural [133]
DKK2
promoter CpG methylation
EMT suppressor by suppressing canonical Wnt/β-catenin signaling
via inhibiting β-catenin activity. Downregulated Anti-tumoural [134]
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Some authors have tried to revert the triple negative character of TNBC patients in order to
give them a chance to benefit from treatments such as trastuzumab (Herceptin®) or tamoxifen
(NCT01194908). It has been demonstrated that ER is not absent in some TNBCs but is epigenetically
silenced by several histone and methyl groups leading to its inactivation. Thus, some clinical trials
have intended to evaluate the effect of epigenetic reprogramming. Histone deacetylase inhibitors such
as LBH589 and demethylating inhibitors can rid of histone- or methyl-group excess; the reactivation of
ER opens the door to use hormonal agents in order to control the growth and the metastasis of TNBCs.
Despite the number of metastatic TNBC clinical trials every year, drug resistance, wide heterogeneity
and high metastasis rate keep TNBC treatment very challenging and epigenetic approaches must be
considered and developed.
7. Conclusions
Triple negative breast cancer is a heterogeneous entity with a high rate of treatment failure
due to the appearance of distant and/or nearby metastases. As a main factor responsible for this
invasive capacity, EMT is an interesting prognostic biomarker and therapeutic target for TNBC patients.
However, its clinical significance has only recently been investigated. Comprehensive new studies
should shed light on EMT-related markers and particularly those implicated in epigenetic mechanisms.
Thus, the study of epigenetic alterations in TNBC, encompassing lncRNAs, miRNAs, histone and
DNA modifications, is a promising area to develop new treatments and EMT-related biomarkers. It is
unlikely however that one epigenetic modification alone would be sufficient to identify robust and
potential biomarkers of TNBC. A global study incorporating different epigenetic markers is necessary
for understanding their role in TNBC. In conclusion, EMT is a promising anticancer target; its epigenetic
alterations can be considered early biomarkers representing potential diagnostic and prognostic factors
in order to define a global metastatic signature for TNBC.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/4/559/s1,
Figure S1: Interactive network of epigenetic factors driving EMT in Triple Negative Breast Cancers.
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